dedup-isc-ft-v107-score
float64 0.3
1
| uid
stringlengths 32
32
| text
stringlengths 1
17.9k
| paper_id
stringlengths 8
11
| original_image_filename
stringlengths 7
69
|
---|---|---|---|---|
0.395576 |
3b2f2bca92b24b10812f8cb3f9200023
|
Description of the main postures of the back reached and maintained by the subject during the implementation of the movement protocol: (a) orthostatic posture maintained before each movement subprotocol and between the repetitions of a given subprotocol; (b) back bent to the left of the subject; (c) back bent to the right of the subject; (d) back bent forward; (e) knees bent, back straight; (f) back bent forward and twisted to the left; (g) back bent forward and twisted to the right; (h) placement of the datalogger, and the datalogger used to collect acceleration data, including axis orientation.
|
PMC9140631
|
healthcare-10-00916-g001.jpg
|
0.48016 |
195f06bebd8840b28ff960867f6836f1
|
An example of the raw data collected by the triaxial accelerometer for the subprotocol A1, involving back bending to the left of the subject: the x, y, and z axes in the legend stand for the responses (g) on x, y, and z axes, respectively; right end part of the figure (from 7050 to 7500 50-ms increments) shows in the responses on the three axes during part of the time in which the orthostatic posture was maintained; relatively static responses in the figure indicate the time in which a given posture was maintained; increments and decrements in magnitude indicate the time in which movements were done to change a given posture. Note: the signal contained impulse noise and oscillations.
|
PMC9140631
|
healthcare-10-00916-g002.jpg
|
0.451225 |
f3fae432eb5746e4ac310b722c629237
|
Data partitioning into training (green strips at the bottom of the figure) and testing (red strips at the bottom of the figure) data subsets. Legend: Xfiltered, Yfiltered, and Zfiltered are the values of the signals on the three axes after applying a median filter with a window size of 41; type of work is an arbitrary signal taking a value of 1 when dynamic work (movement) was present and −1 when static work (no movement) was present.
|
PMC9140631
|
healthcare-10-00916-g003.jpg
|
0.436739 |
93ba741f5714454eb5a0e2cf30091208
|
Effect of axial signal filtering by a median filter with a window size of 41. Legend: Xoriginal, Yoriginal, and Zoriginal are the original values collected by the accelerometer on the x, y, and z axes, respectively; Xfiltered, Yfiltered, and Zfiltered are the values of the signals on the three axes after applying a median filter with a window size of 41; type of work is an arbitrary signal taking a value of 1 when dynamic work (movement) was present and −1 when static work (no movement) was present. Note: the time domain from 0 to ca. 5100 (50 ms increments) corresponds to the subprotocol A1 (Table A1), and the time domain from ca. 5100 to 5500 (50 ms increments) (right part of the figure) corresponds to keeping an orthostatic posture before starting subprotocol A2; details given in black box indicate the utility of the used median filter in removing both impulse noise and oscillations during dynamic work.
|
PMC9140631
|
healthcare-10-00916-g004.jpg
|
0.540995 |
8912a0b5664b46aa83f5dfb94c9f0612
|
Variation in classification accuracy (CA), recall (REC), and cross-entropy (LOGLOSS) by parameter tuning: (a–c) results of the two-class problem of evaluating the classification performance over dynamic and static work by the MLPBNN as a function of the regularization term; (d–f) results of the 13-class problem of evaluating the classification performance over back postures by the MLPBNN as a function of the regularization term; (g–i) results of the two-class problem of evaluating the classification performance over dynamic and static work by the RF as a function of the number of trees; (j–l) results of the 13-class problem of evaluating the classification performance over back postures by the RF as a function of the number of trees.
|
PMC9140631
|
healthcare-10-00916-g005a.jpg
|
0.45516 |
33bb5e58d2d64ead8028534b2e6db65f
|
Classification performance in the training and testing phases to differentiate dynamic from static work: (a) by a MLPBNN machine learning algorithm with α set at 0.001; (b) by a RF machine learning algorithm with number of trees set at 10,000.
|
PMC9140631
|
healthcare-10-00916-g006.jpg
|
0.445903 |
324ddfd77a7c43bc89dfc65d863078ec
|
Misclassifications in the testing phase of the two-class problem (dynamic vs. static work of the back) by the two machine learning algorithms: (a) MLPBPNN (α = 0.001) algorithm; (b) RF (number of trees = 10,000) algorithm. Legend: classifier—an arbitrary signal showing the correct (acceleration = −1.5 g) and incorrect (acceleration = −2.0 g) classifications; Xfiltered, Yfiltered, and Zfiltered are the values of the signals on the three axes after applying a median filter with a window size of 41.
|
PMC9140631
|
healthcare-10-00916-g007a.jpg
|
0.456816 |
d610a667d34149018dd0a0ba4609a576
|
Location of the study region.
|
PMC9140723
|
ijerph-19-06132-g001.jpg
|
0.513843 |
0113f773cd21463c9b2afc2a7dbe3a45
|
The distribution of soil potential toxic element samples in the study region.
|
PMC9140723
|
ijerph-19-06132-g002.jpg
|
0.437554 |
ebe9a5e47d4b47d986a40d4312005d11
|
Spatial distribution of ecological risk index.
|
PMC9140723
|
ijerph-19-06132-g003.jpg
|
0.509229 |
8c4525fa9eaa4b46b46dd7d09293a841
|
Source composition of the PMF model.
|
PMC9140723
|
ijerph-19-06132-g004.jpg
|
0.418781 |
dcd706a214ce4e0a986e3ffcd09907e4
|
Spatial distribution of the source contribution of each sample for six factors from the PMF model.
|
PMC9140723
|
ijerph-19-06132-g005.jpg
|
0.459021 |
50381095fc184edea492b9c9dfe0162c
|
Geometric distributions of eight potential toxic element contents (after normalization).
|
PMC9140723
|
ijerph-19-06132-g006.jpg
|
0.446019 |
f8e6395e478a4ff690b80bc95a1cbe82
|
Spatial distribution of the source contribution of each sample for six factors from the Unmix model.
|
PMC9140723
|
ijerph-19-06132-g007.jpg
|
0.491955 |
0c700891229c414fb0aadd616d23aa37
|
Family pedigree. Black-filled symbols, subjects carrying the identified RET c.1901G>A and SLC12A3 c.3070_3079delinsCAG mutations; empty symbols, subjects without identified mutations; gray-filled symbols, not sequenced; the black arrow indicates the proband.
|
PMC9140906
|
genes-13-00864-g001.jpg
|
0.412791 |
82b939fb40904e3ab71d7844e2487d87
|
The computed tomography of the proband showed multiple nodules on both sides of the adrenal glands.
|
PMC9140906
|
genes-13-00864-g002.jpg
|
0.461231 |
cb0122fc6d8347c8a443c609bc8ea6d2
|
Sanger sequencing identified the mutation in RET.
|
PMC9140906
|
genes-13-00864-g003.jpg
|
0.398796 |
4b2a918a6a2c4b62920f8bf3b84fda91
|
Sanger sequencing identified the mutation in SLC12A3.
|
PMC9140906
|
genes-13-00864-g004.jpg
|
0.453579 |
636f553e7e6442a6aa53518ed43a0c6a
|
Structural models of the protein encoded by SLC12A3 (a) and the mutant (SLC12A3 c.3070_3079delinsCAG) (b). Yellow spheres indicate mutated amino acid residues.
|
PMC9140906
|
genes-13-00864-g005.jpg
|
0.507979 |
3d1a01f80a5c4f529f0b3e9b10527a3b
|
(a,b): Interaction pattern between the C-terminal amino acids and surrounding amino acid residues in the protein encoded by SLC12A3. (c,d): Interaction pattern between the C-terminal amino acids and the surrounding amino acid residues in the predicted protein encoded by SLC12A3 c.3070_3079-delinsCAG. Yellow spheres indicate mutated amino acid residues.
|
PMC9140906
|
genes-13-00864-g006.jpg
|
0.411074 |
3b8dc56cc6bd4d9f8ac0245e282ae16d
|
Conceptual model.
|
PMC9141056
|
foods-11-01375-g001.jpg
|
0.453887 |
1941b0fe88dd471391786929af60aa08
|
Schematic illustration of the preparation process of GelMA HMs and its treatment of skull defects. (A) HMs were fabricated by microfluidic technology with UV irradiation. (B) BMSCs were seeded on the HMs and then transplanted to the skull defects.
|
PMC9141522
|
gels-08-00275-g001.jpg
|
0.407184 |
a44a9df5fd624223acd162250d21be43
|
Physical and biocompatible characterization of HMs. (A) The stereoscopic microscope image of HMs. Scale bar: 500 μm. (B) The microscopic image of HMs. Scale bar: 400 μm. (C) The mechanical strength of HMs. (D) Live/dead staining of BMSCs co-cultured with HMs for 1, 4, and 7 days, respectively. Scale bar: 500 μm. (E) Viability quantification of BMSCs co-cultured with HMs for 1, 4, and 7 days. (F) The toxicity test of HMs and BMSCs co-culture. (G) The cytotoxicity of HMs to BMSCs after culture for 1, 3, 5, and 7 days.
|
PMC9141522
|
gels-08-00275-g002.jpg
|
0.395909 |
46123a467ac848aab7537888be3137d5
|
The effect of HMs on bone marrow mesenchymal stem cells. (A) The expression of osteogenic marker genes (RUNX2, OCN, and BMP2). (B) The expression of chondrogenic marker genes (SOX9 and COLL2). (C) The expression of adipogenic marker genes (PPARγ, LPL, and C/EBPα). (Error bars, mean ±SD; * p < 0.05, *** p < 0.001; n = 3 per group).
|
PMC9141522
|
gels-08-00275-g003.jpg
|
0.423552 |
7b467dbbb8154fe1bc27ce659657c361
|
Evaluation of bone regeneration 8 weeks after surgery by micro-CT. (A) Micromorphometric analysis of large skull defects including superficial, three-dimensional, and sagittal views of micro-CT images after 8 weeks of surgery. (B) Micromorphometric bone parameters including BMD, BV/TV, Tb.Sp, BV, BS/BV, and Tb.Th analysis of control, HMs, and BMSC/HMs groups after 8 weeks of surgery (error bars, mean ± SD; * p < 0.05, ** p < 0.01; n = 3 per group).
|
PMC9141522
|
gels-08-00275-g004.jpg
|
0.446398 |
2001c76020f24843ab2cf67d48d3ed73
|
Histological analysis of bone regeneration 8 weeks after surgery. (A) Representative images for H&E staining in sections of control, HMs, and BMSC/HMs group for 8 weeks. Scale bar: 500 μm. The magnified images for HE staining in different groups in the area of skull defects for 8 weeks. Scale bar: 50 μm. (B) Representative images and magnified images for immunohistochemical staining of OCN-positive cells in the skull defect regions at 8 weeks post implantation in the three different groups. Scale bar of the first row: 50 μm. Scale bar of the second row: 20 μm. (C) Semi-quantitative analysis of the relative numbers of OCN-positive cells in the different groups (n = 3). *** p < 0.001, **** p < 0.0001.
|
PMC9141522
|
gels-08-00275-g005.jpg
|
0.451527 |
c451b5aa061b417295b846c0960584d3
|
The degree of membership of three different channels with (A) M = 64, (B) M = 128, and (C) M = 192.
|
PMC9141659
|
healthcare-10-00962-g001.jpg
|
0.467415 |
a79c1138421e4a0f93dc2d4022fdc1ce
|
Preprocessed Image.
|
PMC9141659
|
healthcare-10-00962-g002.jpg
|
0.373698 |
988879693e5b49f5bf3f5f454142c5b5
|
Segmented lesions.
|
PMC9141659
|
healthcare-10-00962-g003.jpg
|
0.509434 |
8a59d66ffb4548c8918fdd8bf0464a10
|
Block diagram of the proposed model.
|
PMC9141659
|
healthcare-10-00962-g004.jpg
|
0.466823 |
fdbb7d4f2b6a4e569417128bb63545bc
|
Confusion matrix.
|
PMC9141659
|
healthcare-10-00962-g005.jpg
|
0.466502 |
50485c5626104816b68daca1bb86a338
|
LDA analysis chart (A) and radar chart (B) of aroma at different times using the E-nose test.
|
PMC9142104
|
foods-11-01501-g001.jpg
|
0.393364 |
a46b3715fd9346579bcec3cdbf52c6dd
|
Taste value (A) and PCA analysis (B) of E- tongue at different fermentation times. PCA is expressed as the mean of flavor values.
|
PMC9142104
|
foods-11-01501-g002.jpg
|
0.491611 |
57473130a09c41f0b1976fb8ba74dd2b
|
Concentrations of 17 FAA (A) and taste activity value (TAV) of various taste amino acids and total TAV (TTAV) at different times (B).
|
PMC9142104
|
foods-11-01501-g003.jpg
|
0.45381 |
aa27f5fc5b554ba4a9586eae3092a323
|
Schematic diagram of projected points of observed values.
|
PMC9142104
|
foods-11-01501-g004.jpg
|
0.47294 |
4e8614dab6504d5d9ac4a36a8913463b
|
(1A and 1B): MRI shows a retroperitoneal soft tissue tumor, attached to the fourth portion of the duodenum.
|
PMC9142376
|
gr1.jpg
|
0.468813 |
fac8e84828214535a62101a736263cde
|
Intra-operative picture of a large mass in the fourth portion of the duodenum (black arrow).
|
PMC9142376
|
gr2.jpg
|
0.455061 |
3765a17ecaae40839c1615a2b2ad0ec5
|
(3A and 3B): Microphotography showing a spindlecell mesenchymal proliferation in the duodenum sub-mucosa (Fig. 3B). the tumor express the DOG1 (Fig. 3A).
|
PMC9142376
|
gr3.jpg
|
0.441655 |
2cd2a3cbfb4d4c9db77eeda380f3deca
|
Process flow of rolling bearing fault diagnosis based on SVMD and the EP index.
|
PMC9142948
|
sensors-22-03889-g001.jpg
|
0.402626 |
153cfedb5f5b4d0b8fa390296d92fbce
|
Vibration signal s(t) with fault-related impulsive features.
|
PMC9142948
|
sensors-22-03889-g002.jpg
|
0.423686 |
4887dad016c24803b0def34ea16011ff
|
The simulated vibration signal x(t): (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g003.jpg
|
0.446748 |
1a731175ca1d46d286f0a564f8032b39
|
Relationship between the α value and (a) the EP index value and (b) order number of the target mode in each step of α increase.
|
PMC9142948
|
sensors-22-03889-g004.jpg
|
0.488766 |
ebaa0080c0fa49b19f06b1e28b8faa91
|
Results of the simulated vibration signal x(t) obtained using SVMD with αopt = 950.
|
PMC9142948
|
sensors-22-03889-g005.jpg
|
0.484211 |
8ea352c3a99b4162a6fb90b1ac3b4272
|
The EP index values of all modes.
|
PMC9142948
|
sensors-22-03889-g006.jpg
|
0.42643 |
5dfc1cd128be4dcd82843f5a7d2a82e1
|
The optimal target mode: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g007.jpg
|
0.479635 |
fb4e08d11b6045bcb8da1b1131cbb7a4
|
Results of the simulated vibration signal x(t) obtained by VMD.
|
PMC9142948
|
sensors-22-03889-g008.jpg
|
0.457695 |
bb667c037cc14b9887ba88cc3c464cea
|
The target mode obtained by VMD: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g009.jpg
|
0.433917 |
30104932f6df4ddd9e44ff4ed7993b60
|
Rolling bearing testbed.
|
PMC9142948
|
sensors-22-03889-g010.jpg
|
0.45521 |
7b2c70d8705b4d58898be44addd344c4
|
Vibration dataset associated with the inner race fault: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g011.jpg
|
0.497688 |
a92c5365742c497ca698c3cbf3940e8d
|
Relationship between the α value and (a) the EP index value and (b) order number of the target mode at each step of α increase.
|
PMC9142948
|
sensors-22-03889-g012.jpg
|
0.4361 |
21edf869d6564858a256e2af4d8f8f17
|
Results of the vibration dataset associated with the inner race fault obtained using SVMD with αopt = 1450.
|
PMC9142948
|
sensors-22-03889-g013.jpg
|
0.462934 |
7cc59c4381cc40049ce3039a6e6a4fe1
|
The EP index of each mode.
|
PMC9142948
|
sensors-22-03889-g014.jpg
|
0.467398 |
402778dec8a64dd28cf0feb67a907589
|
The optimal target mode: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g015.jpg
|
0.428518 |
77f430f9bb384576be9800387a303be3
|
The target mode obtained by VMD: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g016.jpg
|
0.468278 |
a47d436a96cd49bcb574b0e16ee745ae
|
Vibration dataset associated with the outer race fault: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g017.jpg
|
0.460624 |
125be48650614b95b8c285dadaba5600
|
Relationship between the α value and (a) the EP index value and (b) order number of the target mode at each step of α increase.
|
PMC9142948
|
sensors-22-03889-g018.jpg
|
0.460384 |
18d7e46a52f04fb4aea6d8efee9ca1fd
|
The EP index value of each mode.
|
PMC9142948
|
sensors-22-03889-g019.jpg
|
0.401472 |
dbe2c36065c748e7aecc15b347c7a50e
|
The optimal target mode: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g020.jpg
|
0.452793 |
f815c0b10f6848bdbb56562c53bf3802
|
The target mode obtained by VMD: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g021.jpg
|
0.390555 |
e1706c3a75764a99bfdaff39488b9f06
|
Vibration dataset associated with the ball fault: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g022.jpg
|
0.472879 |
7506cce9331a43baa2e85087ff7d2ad8
|
Relationship between the α value and (a) the EP index value and (b) order number of the target mode at each step of α increase.
|
PMC9142948
|
sensors-22-03889-g023.jpg
|
0.42874 |
9d24409c4b4c4cee85cf3b04f96f52e2
|
Results of the vibration dataset associated with the ball fault obtained using SVMD with αopt = 2700.
|
PMC9142948
|
sensors-22-03889-g024.jpg
|
0.630421 |
3d2294bd24b540a4b91e0552a9d9be90
|
The EP index value of each mode.
|
PMC9142948
|
sensors-22-03889-g025.jpg
|
0.412268 |
e67fec055e1640b9a4354544a532e49e
|
The optimal target mode: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g026.jpg
|
0.416507 |
9718baf7619e4592b3729130a62c815e
|
The target mode obtained by VMD: (a) time−domain waveform and (b) SES.
|
PMC9142948
|
sensors-22-03889-g027.jpg
|
0.384872 |
ca0c1ab439a54feaba267ccbc4a100bf
|
Principal component analysis (PCA) scores plot of metabolome distribution of bulls’ liver among the treatments (NP, PP, and FP).
|
PMC9143101
|
metabolites-12-00441-g001.jpg
|
0.363777 |
0991d9d8cf424ce3bd361804f4f9ac67
|
Top 25 significant correlations between BW and liver metabolites of bulls. Blue bars are negative correlations, pink bars are positive correlations.
|
PMC9143101
|
metabolites-12-00441-g002.jpg
|
0.425335 |
0b14bdb2e5364fc1b2104a50df8cdcc4
|
Top biological processes involved with significant liver metabolites of bulls from the three prenatal nutritional treatments (NP, PP, and FP).
|
PMC9143101
|
metabolites-12-00441-g003.jpg
|
0.398129 |
bbb87dea34ef4e099cc340afb3f04c9c
|
Anamnestic reports given for samples of hay, haylage, and straw submitted for microbiological examination. Other (n = 149, all types of roughage): Allergic symptoms (30), refusal of feed (27), laminitis (15), poor performance (14), sudden death (12), cachexia (11), skin disease (4), swelling (legs) (4), intoxication symptoms (3), official control (3), abortion (3), fungal infection (3), swelling (head) (3), sterility (3), nervous disorders (2), lameness (2), sudden collapse (2), bale inflammation (1), salivation (1), cystitis (1), alteration of blood counts (1), botulism (1), Equine Cushing’s disease (1), fever (1), polyuria (1). G.I.D. = gastrointestinal disorder (n = 195): colic (169), diarrhea (16), or watery stools (10).
|
PMC9143553
|
vetsci-09-00226-g001.jpg
|
0.40874 |
857357f070904d70b1e08e68e1e6ba9f
|
(A) Monthly net income per person in the household among groups differing in influenza vaccination in 2019; (B) Monthly net income per person in the household among groups differing in influenza vaccination in 2020; (C) Monthly net income per person in the household among groups of people with or without a recommendation from a primary care physician for influenza and pneumococcal vaccination; (D) Monthly net income per person in the household among groups of people who differ in the knowledge of influenza vaccine reimbursement for seniors; (E) Monthly net income per person in households that differ in influenza vaccination avoidance due to possible complications, and the significance test results.
|
PMC9143662
|
vaccines-10-00651-g001a.jpg
|
0.434439 |
e600862f858e49658783d09afc31a31b
|
(A) Nutritional status in groups of people that differed in influenza vaccination in 2020 and the result of the significance test; (B) Assessment of the nutritional status in groups of people who were recommended or not by a primary healthcare physician for influenza and pneumococcal vaccination, and the test of significance; (C) Assessment of complex activities of everyday life in groups of people who were recommended or not by a primary healthcare physician to vaccinate against influenza and pneumococci, and the result of the significance test.
|
PMC9143662
|
vaccines-10-00651-g002.jpg
|
0.461604 |
dd7947f694b04776acfcd6d1f33bae71
|
(A) Number (percentage) of people in groups that differed in 2019 influenza vaccination and coexistence of coronary artery disease; (B) The number (percentage) of people in the groups differing in the coexistence of coronary artery disease and the recommendation of a primary healthcare physician to vaccinate against influenza and pneumococci; (C) Number (percentage) of people in groups that differ in the coexistence of coronary artery disease and know about the reimbursement of influenza vaccine for seniors; (D) Number (percentage) of people in groups differing in the coexistence of diabetes and the recommendation of a primary healthcare physician to vaccinate against influenza and pneumococci; (E) The number (percentage) of people in the groups differing in the coexistence of asthma and the recommendation of a primary healthcare physician to vaccinate against influenza and pneumococci; (F) The number (percentage) of people in the groups differing in the coexistence of heart failure and the recommendation of a primary healthcare physician to vaccinate against influenza and pneumococci; (G) Number (percentage) of people in the groups differing in their responses to the question about the willingness to be vaccinated against influenza and the coexistence of COPD and the results of the independence tests.
|
PMC9143662
|
vaccines-10-00651-g003.jpg
|
0.418221 |
3aa7985fdbdb4e7a83ebb3c9a0ac7e45
|
(a) IZO solution based on the metal–nitrate precursor used for manufacturing a-IZO TFT, and the types of ions and by-products that can be produced by dissolution. (b) Schematic illustration of finger-type solution process a-IZO TFT.
|
PMC9143800
|
materials-15-03416-g001.jpg
|
0.350426 |
953ad8017b45467a956b862f1979eb74
|
(a) Cross-section and (b) morphological SEM images of a-IZO films with respect to the Zn molarity ratio. The In molarity ratio used for the fabrication of each a-IZO film was 0.05 M.
|
PMC9143800
|
materials-15-03416-g002.jpg
|
0.459727 |
1583426f1f3d474b96b1d1437daa8a4f
|
XRD graph to analyze the crystallinity of a-IZO films. (a) Reference peak analysis of IZO, InO and ZnO films. (left) Crystallinity of bulk film measured in 2-θ mode. (right) Surface crystallinity measured in grazing incident (GI) mode. Several reference peaks of IZO, InO, ZnO films are indicated at the top of the graph (a). (b) (left) Bulk and (right) crystallinity of the a-IZO films with respect to Zn molarity.
|
PMC9143800
|
materials-15-03416-g003.jpg
|
0.407076 |
48f9dc5abc8f48e38311b3f1da8e0f44
|
XPS results for stoichiometric characterization with respect to the Zn molarity. (a) Zn 2p, (b) In 3d, and (c) O 1s peak analysis of a-IZO films. The bonding energies of 529.8, 531.0, and 532.0 eV suggest M-O, oxygen vacancy (VO), and M-OH bond, respectively.
|
PMC9143800
|
materials-15-03416-g004.jpg
|
0.496989 |
5a1f64ec286940669396081723e8ce5d
|
AES graph in terms of the depth of a-IZO film. Measured results (dashed line) after spin coating and soft baking (110 °C) and (solid line) after annealing at 550 °C.
|
PMC9143800
|
materials-15-03416-g005.jpg
|
0.476758 |
210a63d44cc14cc89fadcc1e88e0eb15
|
TGA result of IZO solution for a-IZO film fabrication. (a) Weight loss versus temperature graph, and (b) enlarged weight loss/differential TGA graph at 100–450 °C.
|
PMC9143800
|
materials-15-03416-g006.jpg
|
0.425382 |
aa61203fd98849d881bda24501462b3d
|
Electrical characteristics of solution-processed a-IZO TFT with respect to the Zn molarity. (a) Transfer curves, (b) output currents, and (c) electrical parameters of the TFT. In (a), the thick/thin lines represent saturation/linear conditions and solid/dashed lines indicate ID/IG, respectively.
|
PMC9143800
|
materials-15-03416-g007.jpg
|
0.409973 |
7daa335810c846d9a73f8310e7f684b8
|
(a) Illustration of types of ions in gel-state a-IZO film after spin coating and the simplest atomic structure by oxidation. (b) Schematic of multi-layer a-IZO film and possible atomic structures of by-product through the annealing process.
|
PMC9143800
|
materials-15-03416-g008.jpg
|
0.46471 |
c5258c86669242568f98cf8412db00dd
|
Model of the Wnt/β-catenin pathway in presence of Wnt ligand. Binding of Wnt to the receptors Frizzled (Fz) and Lrp6 leads to inhibition of β-catenin degradation. After stabilization, β-catenin is translocated into the nucleus and interacts with members of the TCF/Lef-1 family of transcription factors to co-activate expression of numerous oncogenes involved in proliferation and migration, in particular Cyclin D1 and c-myc, as well as other genes, including Twist, Snail, ZEB1, and MITF, thus, facilitating EMT. Created with BioRender.com (accessed on 29 April 2022).
|
PMC9144176
|
vaccines-10-00790-g001.jpg
|
0.448555 |
191f27dcc90c4ac6b70fbad1bdde5730
|
Wnt signaling involves macropinocytosis, V-ATPase, MVBs, membrane trafficking, and lysosomes. Sequestration of GSK3 is a vital step in the activation of the canonical Wnt pathway. When the Wnt ligands bind to the Fz receptor and the Lrp6 co-receptors (Step 1 in yellow), GSK3 is translocated into the membrane. It is then internalized into an early endosome and subsequently into MVBs (Step 2). The sequestration of GSK3 and the destruction complex activate the Wnt pathway (Step 3). Lysosomal activity is critical for dorsal development. Mimicking Wnt signaling with LiCl can dorsalize embryos, an effect that is even more pronounced with LiCl plus HCQ. Inhibiting lysosomal activity with BafA1 or Concanamycin A or interfering with the MVB formation with VPS4-EQ or HRS-MO ventralizes embryos. Wnt and cell adhesion are often active in the same processes and crosstalk between them exists by reciprocal regulation and sharing of components. Knowing how Wnt signaling and cell adhesion cooperate will improve our understanding of embryonic development decisions and carcinomas. Diagram based on findings reported in Tejeda—Muñoz et al., 2022, with permission from Proceeding of the National Academy of Science and Creative Commons.
|
PMC9144176
|
vaccines-10-00790-g002.jpg
|
0.408039 |
0ee2339580424d13851f57536158e357
|
V-ATPases in cancer. The V-ATPase is formed of a peripheral V1 domain, which hydrolyzes ATP and an integral V0 domain that translocates protons. The subunits in the catalytic domain (V1) hydrolyze ATP at the cytosolic side of the membrane. The subunits embedded in the membrane form the proton-translocating domain (Vo) that transfers protons from the cytosol to the vesicle lumen. The effects of inhibiting lysosomal function with the specific vacuolar ATPase (v-ATPase) inhibitors such as BafA1 was reported to result in significantly decreased tumor growth, proliferation, and metastasis through the activation of signaling pathways such as Wnt in several types of cancer.
|
PMC9144176
|
vaccines-10-00790-g003.jpg
|
0.401343 |
7e291266afc34170aa6eb4117bf35078
|
Targeting macropinocytosis as a promising therapeutic strategy for cancer. Macropinocytosis is prominent in several types of cancer, such as colon, pancreatic, lung, prostate, and bladder. Through macropinocytosis, serum proteins and a host of extracellular glycoproteins enter the cellular fluid compartment to either be recycled out of the cell or directed to lysosomes for degradation in order to generate key metabolites that fuel cell growth and proliferation. Vacuolar ATPase (V-ATPase) is an essential regulator of RAS-induced micropinocytosis as well as the serine/threonine p21-activating kinases, known as PAK-1 protein. Several inhibitors can block membrane trafficking, macropinocytosis, and lysosomal activity, which affect tumor growth and reveal its important role in cancer. Therefore, macropinocytosis represents a metabolic vulnerability that can be leveraged to therapeutically target macropinocytic tumors by limiting their access to nutrients.
|
PMC9144176
|
vaccines-10-00790-g004.jpg
|
0.407643 |
46b96a8948454f59afd748d5b42b4860
|
Stepwise elution curve of F and FD1. (A) Stepwise elution curve of F on the DEAE cellulose 52 ion column chromatography column. The fucoidans obtained from 0, 1.3, 2.3 and 3.0 M NaCl eluents were called F0, F1, F2 and F3, respectively. (B) Stepwise elution curve of FD1 on the Superdex 75 gel column chromatography column.
|
PMC9144781
|
marinedrugs-20-00300-g001.jpg
|
0.412707 |
12f0980221c44f049a2864f362c5fd40
|
Monosaccharide composition: (A) F, (B) F1, (C) FD1, (D) FDS1.
|
PMC9144781
|
marinedrugs-20-00300-g002.jpg
|
0.493109 |
dc24f39ae144479da334d8b909c63258
|
FTIR spectrum of sulfated fucoidans: (A) F, (B) F1, (C) FD1, (D) FDS1.
|
PMC9144781
|
marinedrugs-20-00300-g003.jpg
|
0.445674 |
a3e81830dc4d4ffd9f1f6b14ff19e889
|
Cell viability: (A) F1, (B) FD1, (C) FDS1, (D) Adr, (E) Heparin, (F) effects of fucoidan on Adr-induced HUVEC cell viability. Compared with the concentration of fucoidan 0 or Blank, the significance is expressed by * p < 0.05 and ** p < 0.01. Compared with the Adr group, the significant difference is expressed by # p < 0.05. Blank means that HUVEC only exposes DMEM medium. Adr refers to the negative control. Heparin means the positive control.
|
PMC9144781
|
marinedrugs-20-00300-g004.jpg
|
0.539682 |
8b126ec0fc69495aa3cf8e62ac3ffa2f
|
F1, FD1 and FDS1 affects the levels of cytokines secreted by Adr-induced HUVEC: (A) vWF, (B) t-PA, (C) PAI-1, (D) t-PA/PAI-1, (E) TF. Compared with the concentration of fucoidan 0 or Blank, the significance is expressed by * p < 0.05 and ** p < 0.01. Compared with the Adr group, the significant difference is expressed by # p < 0.05 and ## p < 0.01. Blank means that HUVEC only exposes DMEM medium. Control refers to the negative control.
|
PMC9144781
|
marinedrugs-20-00300-g005.jpg
|
0.374752 |
bee7358eeee84b1c86928cd7b0e5127c
|
Patient inclusion flowchart.COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
|
PMC9144838
|
gr1_lrg.jpg
|
0.445361 |
972ec64062a84de68075d1fad61f0cf8
|
VCM platelets of different SR polymers.
|
PMC9145509
|
pharmaceutics-14-00931-g001.jpg
|
0.41439 |
07b4cc072664438b841f28c4b61f0a54
|
Printed polypills in various designs.
|
PMC9145509
|
pharmaceutics-14-00931-g002.jpg
|
0.462022 |
ec32c0e3a1364408a88ad0969ec9efc3
|
Dissolution profiles of LD from SR-polymer-VCM platelets (33% (w/w) LD-loading); modified basket apparatus, 1000 mL 0.1 N HCl, 50 rpm, 37.0 ± 0.5 °C. x ± s; n = 3.
|
PMC9145509
|
pharmaceutics-14-00931-g003.jpg
|
0.444699 |
238be8a5072a474fbfa6341291e5c0ca
|
Dissolution of LD from F1, F2, F3 and F4; modified basket apparatus, 1000 mL 0.1 N HCl, 50 rpm, 37.0 ± 0.5 °C. x ± s; n = 3.
|
PMC9145509
|
pharmaceutics-14-00931-g004.jpg
|
0.391484 |
9b95290faada4948bec86aaf5b1e297b
|
Dissolution of LD/BZ from FC1, FC2, and FC3; modified basket apparatus, 1000 mL 0.1 N HCl, 50 rpm, 37.0 ± 0.5 °C. x ± s; n = 3.
|
PMC9145509
|
pharmaceutics-14-00931-g005.jpg
|
0.432269 |
81f656c42318445fb0ea2d5296b976d7
|
(Left): release profile of PP1; modified basket apparatus, 1000 mL 0.1 N HCl, 50 rpm, 37.0 ± 0.5 °C, x ± s; n = 3. (Right): Image of PP1: red: PDM-PVA, blue: LD/BZ-EVA.
|
PMC9145509
|
pharmaceutics-14-00931-g006.jpg
|
0.461612 |
beb73494aa2044c3b0e22cc1aac83796
|
Floating properties of PP1 in 300 mL 0.1 N HCl, 37 ± 0.5 °C.
|
PMC9145509
|
pharmaceutics-14-00931-g007.jpg
|
0.458578 |
1486b31736994d689a6cf2eb922defb8
|
(Left): release profile of PP2; modified basket apparatus, 1000 mL 0.1 N HCl, 50 rpm, 37.0 ± 0.5 °C, x ± s; n = 3. (Right): Image of PP2: red: PDM-PVA, blue: LD/BZ-EVA.
|
PMC9145509
|
pharmaceutics-14-00931-g008.jpg
|
0.45131 |
220f45a36c884eabb85921d9b73fd8fc
|
Floating properties of PP2 in 300 mL 0.1 N HCl, 37 ± 0.5 °C.
|
PMC9145509
|
pharmaceutics-14-00931-g009.jpg
|
0.434796 |
51f748edffce40cd97696d0ff74afca8
|
(Left): release profile of PP3; modified basket apparatus, 1000 mL 0.1 N HCl, 50 rpm, 37.0 ± 0.5 °C, x ± s; n = 3. (Right): Image of PP3: red: PDM-PVA, blue: LD/BZ-EVA.
|
PMC9145509
|
pharmaceutics-14-00931-g010.jpg
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.